Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 30Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13durvalumab 12Ipilimumab 12Capecitabine 12Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × pomalidomide × Clear all
NCT05083169 2026-05-08

MajesTEC-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
587 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Sanofi

Phase 3 Completed
307 enrolled 32 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡